Betamethasone Dipropionate

證據等級: L5

預測適應症: 0 個

Betamethasone Dipropionate: Drug Repurposing Evaluation Report

One-Sentence Summary

Betamethasone Dipropionate is a potent synthetic corticosteroid widely used for inflammatory and pruritic dermatological conditions. The TxGNN model has not generated any predicted new indications for this drug at this time. There are currently no clinical trials or publications linked to a repurposing candidate, and several critical data gaps remain to be resolved.

Quick Overview

Item	Content
Original Indication	(Data not available in current evidence pack — see note below)
Predicted New Indication	None (no TxGNN predictions generated)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only; no candidate identified
Malaysia Market Status	✓ Marketed (已上市)
Number of Registrations	41
Recommended Decision	Hold

Note on Original Indication: The 41 licence records returned by NPRA all have empty indication text fields. Based on established pharmacological knowledge, Betamethasone Dipropionate is a high-potency topical corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., eczema, psoriasis, dermatitis).

Why is This Prediction Reasonable?

There is no TxGNN prediction to evaluate at this time. The predicted_indications array is empty, meaning the model did not return any drug-repurposing candidates for Betamethasone Dipropionate.

This may be due to one or more of the following reasons:

Missing DrugBank ID mapping: The evidence pack shows drugbank_id: null. Without a valid DrugBank identifier, the TxGNN knowledge graph cannot anchor the drug node and therefore cannot generate repurposing predictions.
Topical corticosteroid limitations: Betamethasone Dipropionate is predominantly used as a topical agent. Drugs with primarily local (non-systemic) mechanisms may have fewer knowledge-graph connections to systemic disease nodes, reducing the likelihood of high-scoring predictions.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, Betamethasone Dipropionate is a synthetic fluorinated corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects by binding to intracellular glucocorticoid receptors, suppressing pro-inflammatory cytokine release, and inhibiting phospholipase A2 activity. This mechanism is well-characterised but the MOA field should be populated from DrugBank to enable proper mechanistic analysis.

Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indication to query against).

Literature Evidence

Currently no related literature available (no predicted indication to query against).

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(empty)	(empty)	(empty)	(empty)
(empty)	(empty)	(empty)	(empty)
(empty)	(empty)	(empty)	(empty)
(empty)	(empty)	(empty)	(empty)
(empty)	(empty)	(empty)	(empty)

Data Quality Issue: All 41 NPRA licence records were returned with empty fields (licence number, product name, dosage form, and approved indication text are all blank). The raw NPRA query was successful (result_count: 41), but the structured data was not parsed into the evidence pack. This must be remediated before the report can be completed.

Safety Considerations

Please refer to the package insert for safety information.

All safety data fields (key warnings, contraindications, drug interactions) are currently unavailable. The DDI query returned zero interactions. These data gaps are classified as Blocking severity — the evaluation cannot proceed to Stage 1 safety screening without them.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate cannot be evaluated because (1) no TxGNN repurposing predictions were generated, likely due to a missing DrugBank ID mapping, and (2) the NPRA licence data, safety warnings, and mechanism of action are all missing or empty. There is no predicted indication to assess.

To proceed, the following is needed:

Resolve DrugBank ID mapping — Query DrugBank for “Betamethasone Dipropionate” (the query log shows a successful DrugBank hit with result_count: 1; the ID should be captured and populated as drugbank_id — expected: DB04315 or parent compound DB00443 for Betamethasone)
Re-parse NPRA licence records — The 41 registrations were found but all fields are empty; re-download and parse the structured data
Populate MOA from DrugBank — Once the DrugBank ID is resolved, retrieve the mechanism of action
Retrieve safety data — Download and parse package insert PDFs from the NPRA/TFDA website for warnings, contraindications, and drug interactions
Re-run TxGNN prediction — With a valid DrugBank ID mapped into the knowledge graph, re-execute the KG and DL prediction pipelines to generate repurposing candidates
Re-generate evidence pack — Once the above gaps are filled, produce a v5 evidence pack and re-run this report

This report was generated on 2026-04-09 based on Evidence Pack v4 (candidate ID: TW-UNKNOWN-multi). Results are for research purposes only and do not constitute medical advice. Any drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.